Matthew G. Ewend, MD
Associate Professor & Chief
Division of Neurosurgery
University of North Carolina at Chapel Hill
Durham, North Carolina
Timothy C. Ryken, MD
Departments of Neurosurgery & Radiation Oncology
University of Iowa
Iowa City, Iowa
Michael A. Vogelbaum, MD, PhD
Associate Director, Brain Tumor & Neuro-Oncology Center
Associate Director, Neurosurgical Oncology
Director, Center for Translational Therapeutics
Cleveland Clinic Foundation
Physician CME: 0.75
Podcast (MP3 & PDF)
CREDIT FOR THIS ACTIVITY IS AVAILABLE FOR PHYSICIANS ONLY.
After a patient is diagnosed with a primary glioma, his or her next appointment is often with a neurosurgeon. Being in the first line of response for a malignant brain tumor makes the neurosurgeon a prominent figure in treatment. However the neurosurgeonís role in managing these patients does not end when the excision is completed. The surgeon is an ongoing part of a multidisciplinary management team that also includes medical oncologists, neuro-oncologists, radiation oncologists, primary care physicians, and other healthcare providers. This podcast features a dialogue between three leading neurosurgeons regarding current treatment approaches, the role of biomarkers, the importance of translational and clinical research, and the future of glioma treatment. Program Developer/Facilitator
. Target Audience
This educational activity is designed to meet the needs of neurosurgeons, neuro-oncologists, radiation oncologists, medical oncologists, and other physicians interested in the treatment of primary gliomas.
Upon completion of this educational activity, the participant should be able to:
Describe the rationale for a multidisciplinary approach to the treatment of primary gliomas.
Explain the concept and theory behind currently available surgical adjuncts, including locally delivered chemotherapy, radiation therapy, and biological agents.
Discuss the role of biomarkers in predicting biological progression of malignant gliomas and potential response to therapeutic intervention.
Review the expanding role of the neurosurgeon in developing clinical translational studies and encouraging their enrollment.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
Dr. Ewend discloses advisory board participation for MGI Pharma, Inc.
Dr. Ryken discloses product consultation and advisory committee service for Medtronic, Inc. He is also on the speakersí bureau for MGI Pharma, Inc., and Schering-Plough Corporation.
Dr. Vogelbaum discloses product consultation and speakersí bureau participation for Schering-Plough Corporation.
This educational activity may contain discussion of investigational uses of pharmaceutical agents or surgical devices. Some of these agents/devices may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Commercial Support Statements
Supported through an educational grant from Schering-Plough.
This program consists of a Podcast/MP3 audio file and a printable PDF of the post-test that can be submitted for credit and/or used to assist learning. You may play the audio online or download the file to an MP3 audio player, such as an iPod. You will also need Adobe Acrobat Reader to view and print the PDF post-test and evaluation.
Click on the "Start program" icon. This will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check/revise existing registration information.
Update your existing registration information, if necessary. When ready, click on the "Continue to Program" icon at the top or bottom of the screen. This will take you to the podcast description page for CMEcorner2go.
Save the PDF file to your computer or open the file using the Adobe Acrobat Reader. Print a copy of the PDF, which includes the post-test and program evaluation. This can be used as a learning aid while you listen to the audio file.
Download or play the audio file by clicking on the appropriate button. Instructions for utilizing this program on a portable MP3 player such as an iPod can be found on this page.
Listen to the presentation before filling out the post-test and evaluation. It should take approximately 45 minutes to listen to the audio and complete the post-test and evaluation.
To receive CME credit, follow the link to the post-test. Succesful completion of the post-test and evaluation online will enable you to immediately print a statement of credit. Alternately, complete the post-test and evaluation found on the last two pages of the PDF. Mail the pages according to the printed instructions. A statement of credit for satisfactory completion of the post-test (70% or better) will be mailed within 6 weeks.
None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in the audio recording are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Schering-Plough. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other healthcare professionals without first evaluating their patientsí conditions, considering possible contraindications or risks, reviewing any applicable manufacturerís product information, and comparing any therapeutic approach with the recommendations of other authorities.